Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203761 | 0.86 | IDO1 (0.34) | MAPTNPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL104443 | 0.83 | HTT (0.42) | MAPTNPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL21461907 | 0.80 | HTT (0.36) | MAPTNPC1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL9989497 | 0.76 | PDGFRB (0.50) | MAPTNPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL8203964 | 0.75 | MGMT (0.33) | MGMTPDGFRBPDGFRAL3MBTL1ABCG2 | |
| SCHEMBL3206770 | 0.75 | RAB9A (0.37) | MAPTNPC1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL30421289 | 0.75 | MGMT (0.38) | MAPTKMT2AOGAMAPK1ALDH1A1 | |
| SCHEMBL20502182 | 0.75 | MGMT (0.38) | MAPTKMT2AOGAMAPK1ALDH1A1 | |
| SCHEMBL13459875 | 0.75 | RAB9A (0.36) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL3594129 | 0.75 | CYP3A4 (0.47) | RAB9AMAOBALDH1A1MGMTPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626864-A1 | LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024118801-A1 | LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4349831-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117222639-A | Quinoline amine compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-110872296-B | dihydro-isoindole-1H-pyrazolo [3,4-d ] pyrimidinone compound, and preparation method and application thereof | 上海弘翊生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1225955-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001032264-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | MAPT 2733/4885NPC1 233/4885RAB9A 3340/4885 |
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | MAPT 2450/4885NPC1 2827/4885RAB9A 1648/4885 |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | QARS1, THEM6, CYP4F11 | MAPT 3133/4885NPC1 194/4885RAB9A 1160/4885 |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | MAPT 2450/4885NPC1 2827/4885RAB9A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.